Opioid prescription by gynecologic oncologists: An analysis of Medicare Part D claims

被引:1
|
作者
Samuel, David [1 ,2 ]
Nevadunsky, Nicole S. [2 ,3 ,4 ]
Miller, Devin T. [2 ,3 ]
Isani, Sara [2 ,3 ,4 ]
Kuo, Dennis Y. S. [2 ,3 ,4 ]
Gressel, Gregory M. [2 ,3 ,4 ]
机构
[1] Montefiore Med Ctr, Dept Obstet & Gynecol & Womens Hlth, 1300 Morris Pk Ave,Block Bldg Rm 628, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, 1300 Morris Pk Ave,Block Bldg Rm 628, Bronx, NY 10461 USA
[3] Montefiore Med Ctr, Div Gynecol Oncol, Dept Obstet & Gynecol & Womens Hlth, Bronx, NY USA
[4] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY USA
关键词
Center for Medicaid and Medicare Services; Gynecologic oncology; Medicare Part D; Opioid; Opioid claim; Opioid epidemic; Opioid prescription; Prescriber demographics; Palliative care;
D O I
10.1016/j.currproblcancer.2020.100655
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The use of opioids across all specialties has increased greatly over the last 2 decades and along with it, opioid misuse, overdose and death. The contribution of opioids prescribed for gynecologic cancers to this problem is unknown. Data from other surgical specialties show prescriber factors including gender, geographic location, board certification, experience, and fellowship training influence opioid prescribing. To characterize national-level opioid prescription patterns among gynecologic oncologists treating Medicare beneficiaries. The Centers for Medicare and Medicaid Services database was used to access Medicare Part D opioid claims prescribed by gynecologic oncologists in 2016. Prescription and prescriber characteristics were recorded including medication type, prescription length, number of claims, and total day supply. Region of practice was determined according to the US Census Bureau Regions. Board certification data were obtained from American Board of Obstetrics and Gynecology website. Bivariate statistical analysis and linear regression modeling were performed using Stata version 14.2. In 2016, 494 board-certified US gynecologic oncologists wrote 24,716 opioid prescriptions for a total 267,824 days of treatment (median 8 [interquartile range {IQR} 6, 11] prescribed days per claim). Gynecologic oncologists had a median of 33 opioid claims (IQR 18, 64). Male physicians had significantly more opioid prescription claims than females ( P < 0.01) including after adjustment for differences in years of experience. There was no difference in prescribed days per claim between male and female physicians. Physicians in the South had the greatest number of opioid prescription claims and significantly more than physicians in all other regions ( P 0.01). Gynecologic oncologists who were board certified for 15 years had a greater number of median opioid claims (28 IQR 16, 50) than those with < 5 years since board certification (22 IQR 15, 38) ( P = 0.04). Physicians who were board certified in palliative care (n = 19) had significantly more opioids claims (median 40; IQR 18, 91) than those without (median 32; IQR 18, 64) ( P < 0.01). In 2016, there were gender-based, regional, and experience-related variations in opioid prescribing by providers caring for Medicare-insured patients. (c) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] The impact of the Medicare Part D prescription benefit on generic drug use
    Zhang, James X.
    Yin, Wesley
    Sun, Shawn X.
    Alexander, G. Caleb
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2008, 23 (10) : 1673 - 1678
  • [42] Prescription drug advertising and drug utilization: The role of Medicare Part D
    Alpert, Abby
    Lakdawalla, Darius
    Sood, Neeraj
    JOURNAL OF PUBLIC ECONOMICS, 2023, 221
  • [43] SOURCES OF REGIONAL VARIATION IN MEDICARE PART D PRESCRIPTION DRUG SPENDING
    Donohue, J. M.
    Morden, N.
    Gellad, W. F.
    Bynum, J.
    Hanlon, J. T.
    Zhou, W.
    Skinner, J.
    GERONTOLOGIST, 2011, 51 : 180 - 180
  • [44] Medicare Part D prescription trends in the use and cost of dermatology medications
    Hwang, Angelina S.
    Pollock, Jordan R.
    Buras, Matthew R.
    Mangold, Aaron R.
    Swanson, David L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (04) : 916 - 918
  • [45] The effect of the medicare Part D prescription benefit on drug utilization and expenditures
    Yin, Wesley
    Basu, Anirban
    Zhang, James X.
    Rabbani, Atonu
    Meltzer, David O.
    Alexander, G. Caleb
    ANNALS OF INTERNAL MEDICINE, 2008, 148 (03) : 169 - 177
  • [46] Correlation of antimicrobial prescription rate and county income in medicare part D
    Volpi, Connor
    Shehadeh, Fadi
    Mylonakis, Eleftherios
    MEDICINE, 2019, 98 (22)
  • [47] Medicare Part D and Quality of Prescription Medication Use in Older Adults
    Lau, Denys T.
    Briesacher, Becky A.
    Touchette, Daniel R.
    Stubbings, JoAnn
    Ng, Judy H.
    DRUGS & AGING, 2011, 28 (10) : 797 - 807
  • [48] MEDICARE PART D PRESCRIPTION PAYMENTS BY PRESCRIBER SPECIALTY TYPE IN 2017
    Li, C.
    Fahim, S. M.
    Westrick, S. C.
    Qian, J.
    VALUE IN HEALTH, 2020, 23 : S298 - S298
  • [49] A cross-sectional analysis of opioid prescribing patterns among gynecologic oncologists using Medicare fee-for-service provider utilization and payment data
    Samuel, D.
    Miller, D. T.
    Isani, S.
    Kuo, D. Y. S.
    Gressel, G. M.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 166 - 166
  • [50] Medicare Part D Spending on Drugs Prescribed by Oncologists: Temporal Trends and Regional Variation
    Ziakas, Panayiotis D.
    Mylonakis, Eleftherios
    JCO ONCOLOGY PRACTICE, 2021, 17 (03) : 150 - +